Productively combining proteasome inhibition with the immunotherapy of cancer.
Sayers
Thomas
T
SAIC-Frederick Inc., National Cancer Institute Frederick, Frederick, MD 21702-1201, USA. sayerst@mail.nih.gov
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D019496:Cancer Vaccines / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D019496:Cancer Vaccines; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex